Pharmaceutical sector targets high growth in 2011

Vietnam’s strongly increasing demand on medicine created favourable conditions for pharmaceutical firms to gain growth in coming time.

Imexpharm Pharmaceutical Joint Stock Co-IMP

In 2010, IMP expected to attain 95-97 billion dong of profit.
Of which, in Jan-Sep 2010, IMP’s accumulated pre tax profit was 77.34 billion dong, fulfilling 96.68 percent of the year’s plan.

In 2011, IMP targets to reach revenue and profit growth at 10-15 percent year-on-year.

On December 31, 2010 the company closed the list of shareholders to offer 4.3 million shares to the public to hike its chartered capital to 160 billion dong.

Hau Giang Pharmaceutical JSC- DHG

Ending 2010, the holding company’s expected revenue was about 1.92 trillion dong and pre tax profit at 370 billion dong, exceeding 20 percent of the year’s target.

In 2011, DHG targets to reach about 15 percent revenue and profit growth.

Cuu Long Pharmaceutical JSC-DCL

In 2010, DCL posted revenue of 750 billion dong and after tax profit at 70-75 billion dong.

Under the resolution of the company’s shareholders’ meeting, DCL plans to pay 20 percent dividend basing on the company’s new chartered capital (198.2 billion dong). But, in 2010, the company has not increased chartered capital yet, so the 2010 dividend would be 25-30 percent dividend in cash.

In 2011, DCL expects to gain 1.2 trillion dong in revenue and after tax profit accounts for 10 percent of revenue. DCL also plans to finalise increasing its charter capital to 198.2 billion dong.

OPC Pharmaceutical JSC – OPC

In 2010, OPC’s estimated revenue was 350 billion dong, pre tax profit at 62 billion dong, exceeding the year’s target.

In 2011, the company’s expected revenue would be 340 billion dong and pre tax profit at 59 billion dong.

Currently, OPC is building its GMP-WHO standard factory in the southern province of Binh Duong with a total investment of 160 billion dong. As planned, the company would put into operation the factory in 2011.

Traphaco JSC-TRA

In 2010, TRA expected to finalise the revenue target of 900 billion dong, 61 billion dong of after tax profit and 20 percent dividend payout in cash (the shareholders book was closed on January 11, 2011).

In 2011, the company is studying to merge Traphaco Co-CNC (capital of 30 billion dong) into TRA. At present, the consultant Kim Long Securities Co is finalising dossier for the merger to submit to the upcoming shareholders’ meeting.

Tags: Vietnam Pharmaceutical sector